

Cancer Partnerships Working Group

Working Group Leadership : Ratain and McLeod

Working Group Membership: David Flockhart, Deanna Kroetz, Dick Weinshilboum, Todd Skaar, Jim Ingle, Mary Relling, Federico Innocenti, Kathy Giacomini, Nancy Cox, Mike Province, Liewei Wang, Dan Hayes

U Chicago, UNC-Chapel Hill, Indiana U, UCSF, Mayo, St Jude, WashU, U Michigan

Working Group Charge

- **Develop a process to optimize the conduct of pharmacogenetic genome-wide association studies in collaboration with publicly funded cancer trials groups**

Tasks

1. ***Design one or more genome-wide pharmacogenetic studies*** in collaboration with the NCI Cooperative Groups
2. ***Develop a plan for whole genome typing*** for specimens obtained from the NCI Cooperative Groups
3. ***Initiate one or more genome-wide pharmacogenetic studies*** in collaboration with the NCI Cooperative Groups
4. ***Execute one or more master agreements*** with the Cooperative Groups
5. ***Identify additional NCI Cooperative Groups*** for which there may be opportunities for collaboration



Cancer Partnerships Working Group

- **11/06: identification of Riken Institute (Yusuke Nakamura, MD, PhD) as potential partner**
- **1/07: preliminary commitment by Dr. Nakamura to collaborate**
- 3/07: meeting with CALGB regarding study of bevacizumab and gemcitabine toxicity (phase III study in pancreatic cancer)
- 4/07: meeting with COG regarding study of predictors of osteonecrosis in children
- 4/07: meeting with Dr. Nakamura
- 6/07: CALGB database completed
- 7/07: CALGB protocol amendment
- 9/07: CTEP approval
- 11/07: RIKEN IRB approval
- 12/07-1/08: SNP scan
- 2/08: Visit to Japan, resulting in commitment for ~6 additional genome scans
- 2/08: Data analysis
- XX 08: Publication submission



RIKEN SNP RESEARCH CENTER



Director
Yusuke Nakamura
(M.D., Ph.D.)

Advisory Council

Research Group for Genotyping
Group Director : Michiaki Kubo (M.D., Ph.D.)

Laboratory for Genotyping
Laboratory Head : Michiaki Kubo (M.D., Ph.D.)

Research Group for Medical Informatics
Group Director : Naoyuki Kamatani (M.D., Ph.D.)

Laboratory for Medical Informatics
Laboratory Head : Tatsuhiko Tsunoda (Ph.D.)

Laboratory for Statistical Analysis
Laboratory Head : Naoyuki Kamatani (M.D., Ph.D.)

Research Group for Disease-causing Mechanism
Group Director : Toshihiro Tanaka (M.D., Ph.D.)

Laboratory for Cardiovascular Diseases
Laboratory Head : Toshihiro Tanaka (M.D., Ph.D.)

Laboratory for Rheumatic Diseases
Laboratory Head : Kazuhiko Yamamoto (M.D., Ph.D.)

Laboratory for Bone and Joint Diseases
Laboratory Head : Shiro Ikegawa (M.D., Ph.D.)

Laboratory for Genetics of Allergic Diseases
Laboratory Head : Mayumi Tamari (M.D., Ph.D.)

Laboratory for Diabetic Nephropathy
Laboratory Head : Shiro Maeda (M.D., Ph.D.)

Laboratory for Obesity
Laboratory Head : Kikuko Hotta (M.D., Ph.D.)

Laboratory for Liver Diseases
Laboratory Head : Kazuaki Chayama (M.D., Ph.D.)

Laboratory for Gastrointestinal Diseases
Laboratory Head : Akira Hata (M.D., Ph.D.)

Laboratory for Pharmacogenetics
Laboratory Head : Taisei Mushiroda (M.D., Ph.D.)

Cancer Partnerships Working Group

- 11/06: identification of Riken Institute (Yusuke Nakamura, MD, PhD) as potential partner
- 1/07: preliminary commitment by Dr. Nakamura to collaborate
- 3/07: meeting with CALGB regarding study of bevacizumab and gemcitabine toxicity (phase III study in pancreatic cancer)
- 4/07: meeting with COG regarding study of predictors of osteonecrosis in children
- 4/07: meeting with Dr. Nakamura
- 6/07: CALGB database completed
- 7/07: CALGB protocol amendment
- 9/07: CTEP approval
- 11/07: RIKEN IRB approval
- 12/07-1/08: SNP scan
- 2/08: Visit to Japan, resulting in commitment for ~6 additional genome scans
- 2/08: Data analysis
- XX 08: Publication submission